Sangamo Therapeutics, Inc. (SGMO) Earnings History
Annual and quarterly earnings data from 1999 to 2024
Loading earnings history...
SGMO EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SGMO Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | -179.9% | -169.4% |
| 2023 | 100.0% | -155.5% | -146.3% |
| 2022 | 89.1% | -180.8% | -172.8% |
| 2021 | 100.0% | -165.6% | -161.1% |
| 2020 | -52.8% | -109.6% | -102.4% |
Download Data
Export SGMO earnings history in CSV or JSON format
Free sign-in required to download data
Sangamo Therapeutics, Inc. (SGMO) Earnings Overview
As of May 8, 2026, Sangamo Therapeutics, Inc. (SGMO) reported trailing twelve-month net income of -$109M, reflecting +66.9% year-over-year growth. The company earned $-0.36 per diluted share over the past four quarters, with a net profit margin of -169.4%.
Looking at the long-term picture, SGMO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$4M in fiscal 1999.
Sangamo Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including EDIT (-$160M net income), CRSP (-$569M net income, -16569.8% margin), BEAM (-$65M net income, -57.2% margin), SGMO has comparable earnings metrics. Compare SGMO vs EDIT →
SGMO Earnings vs Peers
Earnings metrics vs comparable public companies
SGMO Historical Earnings Data (1999–2024)
26 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$98M | +62.0% | -$104M | $-0.49 | -169.4% | -179.9% |
| 2023 | -$258M | -34.1% | -$274M | $-1.48 | -146.3% | -155.5% |
| 2022 | -$192M | -7.8% | -$201M | $-1.25 | -172.8% | -180.8% |
| 2021 | -$178M | -47.3% | -$183M | $-1.23 | -161.1% | -165.6% |
| 2020 | -$121M | -27.1% | -$130M | $-0.90 | -102.4% | -109.6% |
| 2019 | -$95M | -39.3% | -$105M | $-0.68 | -92.9% | -102.7% |
| 2018 | -$68M | -25.2% | -$77M | $-0.70 | -80.9% | -91.4% |
| 2017 | -$55M | +23.8% | -$56M | $-0.70 | -149.2% | -154.1% |
| 2016 | -$72M | -76.1% | -$73M | $-1.02 | -369.6% | -374.2% |
| 2015 | -$41M | -54.1% | -$47M | $-0.58 | -102.9% | -118.5% |
See SGMO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SGMO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SGMO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSGMO — Frequently Asked Questions
Quick answers to the most common questions about buying SGMO stock.
Is SGMO growing earnings?
SGMO EPS is $-0.36, with earnings growth accelerating to +66.9%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-109M.
What are SGMO's profit margins?
Sangamo Therapeutics, Inc. net margin is -169.4%, with operating margin at -179.9%. Below-average margins reflect competitive or cost pressures.
How consistent are SGMO's earnings?
SGMO earnings data spans 1999-2024. The accelerating earnings trend is +66.9% YoY. Historical data enables comparison across business cycles.